<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01907568</url>
  </required_header>
  <id_info>
    <org_study_id>UH-1</org_study_id>
    <secondary_id>NL42959.041.13</secondary_id>
    <nct_id>NCT01907568</nct_id>
  </id_info>
  <brief_title>Understanding Hallucinations (Part I)</brief_title>
  <acronym>UH-1</acronym>
  <official_title>Understanding Hallucinations (Part I) - Phenomenology and Cognition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Free University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parnassia Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psychotic symptoms (hallucinations and delusions) are present in several psychiatric and
      neurological disorders as well as in the general population. Effective treatment strategies
      for these symptoms in all patients are lacking and treatment-response can presently not be
      predicted. To date, the exact pathophysiological mechanism of these symptoms remains unknown.
      By investigating (subtypes) of hallucinations and delusions in all populations, a common
      pathway may be found, leading to more effective treatment options. Alternatively, different
      subtypes may be associated with different pathophysiological mechanisms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of clusters of patients with shared symptom profiles as determined by latent class analysis, and the difference in scores on cognitive assessment between these identified clusters.</measure>
    <time_frame>Three years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The internal consistency, test-retest reliability, inter-rater reliability, criterion validity and construct validity of a newly developed questionnaire.</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in scores on cognitive assessment between participant groups with and without psychotic symptoms.</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <number_of_groups>11</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Hallucinations</condition>
  <condition>No Hallucinations</condition>
  <arm_group>
    <arm_group_label>Patients with schizophrenia</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with borderline personality disorder</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with hearing impairment</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with visual loss</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Parkinson's Disease</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Alzheimer's Disease</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with dementia with Lewy Bodies</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Posttraumatic Stress Disorder</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with delirium</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy participants</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with mood disorder</arm_group_label>
    <description>With and without hallucinations</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        We aim to include subjects of each of the following diagnostic groups, both with and
        without psychotic symptoms:

          1. patients with schizophrenia spectrum disorders

          2. patients with borderline personality disorder (BPD)

          3. patients with hearing impairment

          4. patients with visual loss

          5. patients with Parkinson's disease (PD)

          6. patients with Alzheimer's disease (AD)

          7. patients with Lewy Body dementia (DLB)

          8. patients with post-traumatic stress disorder (PTSD)

          9. patients with delirium

         10. healthy individuals

         11. patients with mood disorder
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  mentally competent

          -  in case of delirium: family member able to give informed consent

          -  Individuals with hallucinations will have to experience at least one episode of
             hallucinations over the last month.

          -  Individuals without hallucinations: no current hallucinations and a history of maximum
             1 episode of hallucinations with a maximum duration of 1 week, at least two years ago.

        Exclusion Criteria:

          -  Age &lt;18)

          -  Participants that cannot read, speak or understand Dutch

          -  For all included diagnostic groups except delirium: Mentally incompetent individuals
             who are not capable to provide informed consent, as determined by their treating
             physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iris Sommer, Prof, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teus van Laar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Scheltens, Prof, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Slotema, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parnassia Groep</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mascha M.J. Linszen, MD</last_name>
    <phone>+31887557468</phone>
    <email>m.m.j.linszen@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie M. Heringa, PhD</last_name>
    <email>s.m.heringa@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mascha Linszen, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Odile van den Heuvel, MD, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Philip Scheltens, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Odile van den Heuvel, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelien Lemstra, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Foncke, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parnassia Bavo Groep</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Slotema, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Karin Slotema, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joop de Jong, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Marthe Meppelink, MD</last_name>
    </contact>
    <investigator>
      <last_name>Teus van Laar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Marthe Meppelink, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marouska van Ommen, BSc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mascha Linszen, MD</last_name>
      <phone>+31887557468</phone>
      <email>m.m.j.linszen@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Sophie Heringa, PhD</last_name>
      <phone>+31887557468</phone>
      <email>s.m.heringa@umcutrecht.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Iris Sommer, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Remko van Lutterveld, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanne Koops, Msc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arjen Slooter, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Heringa, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maya Schutte, Msc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mascha Linszen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2013</study_first_submitted>
  <study_first_submitted_qc>July 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Iris Sommer</investigator_full_name>
    <investigator_title>Prof.Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hallucinations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

